Tactile Systems Technology, Inc. (TCMD)
| Market Cap | 570.35M +78.0% |
| Revenue (ttm) | 329.52M +12.5% |
| Net Income | 19.09M +12.5% |
| EPS | 0.82 +17.1% |
| Shares Out | 22.75M |
| PE Ratio | 30.57 |
| Forward PE | 22.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,068 |
| Open | 24.46 |
| Previous Close | 24.45 |
| Day's Range | 24.11 - 26.87 |
| 52-Week Range | 8.61 - 37.77 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+43.6%) |
| Earnings Date | May 4, 2026 |
About TCMD
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic comp... [Read more]
Financial Performance
In 2025, TCMD's revenue was $329.52 million, an increase of 12.47% compared to the previous year's $292.98 million. Earnings were $19.09 million, an increase of 12.54%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TCMD stock is "Strong Buy." The 12-month stock price target is $36.0, which is an increase of 43.60% from the latest price.
News
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...
Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...
Tactile Systems Technology Analysts Raise Their Forecasts After Better-Than-Expected Q4 Earnings
Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributa...
Tactile Systems Technology Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 12% revenue growth, margin expansion, and record Q4 performance. 2026 guidance anticipates 8%-11% growth, factoring in a short-term Medicare prior authorization headwind. Acquisition of LymphaTech and new product launches support long-term growth.
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
LymphaTech's 3D Platform and Digital Capabilities to Improve Disease Identification, Accelerate Therapy Adoption, and Support Next-Generation Lymphatic Therapies LymphaTech's 3D Platform and Digital C...
Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Systems Technology Transcript: Piper Sandler 37th Annual Healthcare Conference
Strong Q3 results and market leadership in both lymphedema and airway clearance were driven by strategic investments, salesforce transformation, and product innovation. Regulatory clarity and new clinical data are expected to further boost growth, with double-digit expansion anticipated in both core segments.
Tactile Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Systems Technology Analysts Increase Their Forecasts After Better-Than-Expected Q3 Earnings
Tactile Systems Technology Inc (NASDAQ:TCMD) reported upbeat third-quarter earnings and raised FY2025 sales guidance on Monday.
Tactile Systems Technology Earnings Call Transcript: Q3 2025
Q3 2025 saw 17% revenue growth, margin expansion, and strong gains in both lymphedema and airway clearance segments. Guidance for 2025 was raised, supported by operational investments, new product launches, and favorable Medicare policy changes.
Tactile Systems Technology, Inc. Reports Third Quarter 2025 Financial Results
MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch® Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema
MINNEAPOLIS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025
MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Systems Technology Earnings Call Transcript: Q2 2025
Q2 revenue rose 7.8% YoY to $78.9M, with strong airway clearance growth and improved gross margin, though adjusted EBITDA declined due to planned investments. FY2025 guidance was raised modestly, reflecting confidence in execution but caution around scaling and tech rollouts.
Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Systems Technology Transcript: Jefferies Global Healthcare Conference 2025
A large, underserved market in lymphedema and bronchiectasis is being addressed through innovative, portable devices, robust clinical evidence, and digital patient engagement. Strategic investments in technology, sales, and education support profitable growth and expanded market access.
Tactile Systems Technology Transcript: 45th Annual William Blair Growth Stock Conference
A $10 billion addressable market in lymphedema and bronchiectasis is being targeted with innovative, tech-enabled therapies and a robust clinical evidence base. Strategic investments in sales, technology, and patient engagement are set to drive continued growth and market leadership.
New Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer Survivors
Abstract Presented at ASCO 2025 Annual Meeting Features Two-Month Data from the Largest Randomized Trial Ever Conducted Among Head and Neck Cancer Survivors Abstract Presented at ASCO 2025 Annual Meet...
Tactile Medical to Present at Upcoming Investor Conferences in June
MINNEAPOLIS, May 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chron...
Tactile Systems Stock Tumbles As Q1 Earnings Fall Short Of Expectations
Tactile Systems Technology, Inc. TCMD traded lower on Tuesday after the company's Q1 earnings missed Wall Street expectations on Monday.
Tactile Systems Technology Earnings Call Transcript: Q1 2025
Q1 revenue was flat year-over-year as lymphedema sales declined and airway clearance grew 22%. Gross margin improved, but adjusted EBITDA turned negative due to tech investments. 2025 guidance was lowered for lymphedema but raised for airway clearance, with strong cash reserves and ongoing sales force expansion.
Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chron...
Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...